Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
15/5 12:45
Ozempic, Ozempic, Ozempic. As we all know, Novo Nordisk's (NYSE: NVO) highly successful drug for type 2 diabetes is grabbing headlines, shrinking waistlines and enriching investors....